RecruitingNot ApplicableNCT04859335

Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma

Prospective Study : Long-term Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma EQUI-GAMMA


Sponsor

University Hospital, Toulouse

Enrollment

50 participants

Start Date

May 21, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

Vestibular schwannomas are benign lesions of the ponto-cerebellar angle that are potentially dangerous because of their growth in a cramped space and the compressive phenomena they can cause. Stereotactic Gammaknife radiosurgery is a treatment option that can be offered for evolutive schwannomas smaller than 2.5-3 cm in size. It allows tumor stabilisation in 85% of cases with less than 1% facial nerve damage risk. There are controversial results regarding hearing preservation : percentages vary between 25 and 80% in the literature, depending on the criteria used and the post-treatment delay. Few studies have investigated changes in vestibular function and the impact on balance of radiosurgery, and their results are variable. These controversial results lead us to comprehensively assess the vestibular function and balance of these patients using a balance-specific quality of life questionnaire, in addition to objective overall vestibular assessments of vestibular function.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria3

  • Vestibular schwannoma's Patients for whom an indication of gammaknife radiosurgery was determined in a dedicated multidisciplinary consultation meeting, having not received previous treatment for this schwannoma.
  • Patient affiliated to Social Security
  • No opposition to participation

Exclusion Criteria5

  • History of prior treatment for the presented vestibular schwannoma (surgery, fractional radiotherapy)
  • History of otological or otoneurological pathology associated with schwannoma
  • Patient with type 2 neurofibromatosis
  • Patient under legal protection
  • Pregnant or breastfeeding women

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONgammaknife radiosurgery

Patients will undergo questionnaires before the gammaknife radiosurgery, then one year and three years after the intervention.


Locations(1)

CHU Toulouse

Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04859335


Related Trials